Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | PYGB | P11216 | 2/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | IGF2R | P11717 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792078 | 1.00 | SELP (0.45) | SELPCA12CA1CA2CA4 | |
| SCHEMBL27806724 | 1.00 | SELP (0.45) | SELPCA12CA1CA2CA4 | |
| SCHEMBL3291698 | 0.90 | SELP (0.47) | SELPCA12CA1CA2CA4 | |
| SCHEMBL27974501 | 0.90 | SELP (0.47) | SELPCA12CA1CA2CA4 | |
| SCHEMBL12198733 | 0.82 | PYGB (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL2302510 | 0.82 | PYGB (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL2507136 | 0.82 | PYGB (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL28909019 | 0.82 | LGALS1 (0.48) | SELPCA12CA1CA2CA4 | |
| SCHEMBL20161429 | 0.82 | LGALS1 (0.48) | SELPCA12CA1CA2CA4 | |
| SCHEMBL7199426 | 0.82 | LGALS1 (0.48) | SELPCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7862804-B2 | Admistration of C-glycoside compounds for depigmenting/whitening the skin | LOREAL (FR) | 2011-01-04 | — | — | US | claimed |
| EP-1774990-B1 | Use of c-glycosides for depigmenting skin | OREAL (FR) | 2009-12-09 | — | — | EP | claimed |
| US-20070081956-A1 | Admistration of C-glycoside compounds for depigmenting/whitening the skin | L'OREAL (FR) | 2007-04-12 | — | — | US | claimed |
| US-7049300-B2 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL (FR) | 2006-05-23 | — | — | US | claimed |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | SOCIETE L'OREAL S.A. (FR) | 2004-03-11 | — | — | US | claimed |
| WO-2023118005-A1 | COMPOSITION CONTAINING THE COMBINATION OF A C-GLYCOSIDE AND ESCIN FOR THE CARE OF THE EYE AREA | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| US-9421157-B2 | Use of C-glycoside derivatives as pro-desquamating active agents | L'OREAL (FR) | 2016-08-23 | — | — | US | disclosed |
| WO-2013088368-A2 | USE OF THE MMP-12 PROTEIN IN THE PREVENTION AND/OR TREATMENT OF AGED OR SENESCENT SKIN | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
| US-8445459-B2 | Combination of monosaccharide with C-glycoside derivative and use thereof | L'OREAL (FR) | 2013-05-21 | — | — | US | disclosed |
| US-7862804-B2 | Admistration of C-glycoside compounds for depigmenting/whitening the skin | LOREAL (FR) | 2011-01-04 | — | — | US | disclosed |
| US-20100190742-A1 | COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISING HYALURONIC ACID AND ADMINISTRATION THEREOF FOR REDUCING SIGNS OF AGING | L'OREAL (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100168055-A1 | COMBINATION OF MONOSACCHARIDE WITH C-GLYCOSIDE DERIVATIVE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | disclosed |
| WO-2008004165-A2 | USE OF C-GLYCOSIDE DERIVATIVES AS PRO-DESQUAMATING ACTIVE AGENTS | L'OREAL (FR) | 2008-01-10 | — | — | WO | disclosed |
| US-20080008673-A1 | Compositions comprising at least one C-glycoside derivative | L'OREAL S.A. (FR) | 2008-01-10 | — | — | US | disclosed |
| US-20080008674-A1 | Use of C-glycoside derivative for improving the skin's barrier function | L'OREAL (FR) | 2008-01-10 | — | — | US | disclosed |
| US-20080003191-A1 | Composition combining a C-glycoside derivative and an emulsifying polymer | L'OREAL (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20070081956-A1 | Admistration of C-glycoside compounds for depigmenting/whitening the skin | L'OREAL (FR) | 2007-04-12 | — | — | US | disclosed |
| US-20060223763-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL S.A. (FR) | 2006-10-05 | — | — | US | disclosed |
| US-7049300-B2 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | L'OREAL (FR) | 2006-05-23 | — | — | US | disclosed |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | SOCIETE L'OREAL S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008673-A1 | Compositions comprising at least one C-glycoside derivative | DSG1, TYR, CUTA | SELP 1538/4885CA12 424/4885CA1 1482/4885 |
| US-20070081956-A1 | Admistration of C-glycoside compounds for depigmenting/whitening the skin | TYR, CAT, NQO1 | SELP 1067/4885CA12 1885/4885CA1 4501/4885 |
| US-20060223763-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | CSGALNACT1, FUT6, AREG | SELP 563/4885CA12 372/4885CA1 2120/4885 |
| US-20100190742-A1 | COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISING HYALURONIC ACID AND ADMINISTRATION THEREOF FOR REDUCING SIGNS OF AGING | GLA, CD44, FUT6 | SELP 3075/4885CA12 503/4885CA1 1072/4885 |
| US-20040048785-A1 | C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | CSGALNACT1, FUT6, AREG | SELP 563/4885CA12 372/4885CA1 2120/4885 |
| US-20080008674-A1 | Use of C-glycoside derivative for improving the skin's barrier function | CUTA, UGCG, GLA | SELP 780/4885CA12 302/4885CA1 3458/4885 |
| US-20080003191-A1 | Composition combining a C-glycoside derivative and an emulsifying polymer | CUTA, UGCG, PSAP | SELP 294/4885CA12 854/4885CA1 3861/4885 |
| US-20100168055-A1 | COMBINATION OF MONOSACCHARIDE WITH C-GLYCOSIDE DERIVATIVE AND USE THEREOF | UGCG, FUT6, MANBA | SELP 482/4885CA12 284/4885CA1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.